### ICELAND (1990-2014)

#### Number of cases

<table>
<thead>
<tr>
<th>Age group</th>
<th>0-1</th>
<th>1-4</th>
<th>5-9</th>
<th>10-14</th>
<th>15-19</th>
<th>0-14</th>
<th>0-19</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Percentage

<table>
<thead>
<tr>
<th>Category</th>
<th>0-14</th>
<th>0-19</th>
<th>All Group</th>
<th>All Group</th>
<th>0-14</th>
<th>0-19</th>
<th>All Group</th>
<th>All Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Hodgkin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Non-Hodgkin except BL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c. Burkitt (BL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>d. Lymphoreticular</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>e. Unspecified</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Incidence rates per million person-years

<table>
<thead>
<tr>
<th>Category</th>
<th>0-14</th>
<th>0-19</th>
<th>All Group</th>
<th>All Group</th>
<th>0-14</th>
<th>0-19</th>
<th>All Group</th>
<th>All Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. Ependymoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Astrocytoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c. CNS embryonal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>d. Other gliomas</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>e. Other specified</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>f. Unspecified CNS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### MV & DCO

<table>
<thead>
<tr>
<th>Category</th>
<th>0-14</th>
<th>0-19</th>
<th>All Group</th>
<th>All Group</th>
<th>0-14</th>
<th>0-19</th>
<th>All Group</th>
<th>All Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>a. CNS neoplasms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>b. Nervous system</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>c. Retinoblastoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>d. Renal tumours</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>e. Unspecified</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>f. Other tumours</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>g. Other specified</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>h. Unspecified</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### References

- International Incidence of Childhood Cancer Volume III: http://icc.icc.icrresults.com

† includes 36 non-malignant ‡ includes 1 non-malignant
<table>
<thead>
<tr>
<th>Category</th>
<th>Number of cases in age groups</th>
<th>ASR per million</th>
<th>M/F ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>LEUKAEMIA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Lymphoid</td>
<td>3 10 10 6 8</td>
<td>35 43</td>
<td>1.1 1.2</td>
</tr>
<tr>
<td>b. Acute myeloid</td>
<td>0 2 0 1 5</td>
<td>8 3.8</td>
<td>0.8 1.6</td>
</tr>
<tr>
<td>c. CMD</td>
<td>0 0 0 1 1</td>
<td>1 1.0</td>
<td>0.5 0.2</td>
</tr>
<tr>
<td>d. MDS &amp; others</td>
<td>1 1 0 0 0</td>
<td>2 3.2</td>
<td>2.0 3.0</td>
</tr>
<tr>
<td>e. Unspecified</td>
<td>1 0 0 0 0</td>
<td>1 1.4</td>
<td>1.1 -</td>
</tr>
<tr>
<td><strong>LYMPHOMA &amp; RELATED</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Hodgkin</td>
<td>3 10 4 26</td>
<td>17 43</td>
<td>4.3 2.9</td>
</tr>
<tr>
<td>b. Non-Hodgkin except BL</td>
<td>0 1 0 19</td>
<td>6 25</td>
<td>3.0 2.3</td>
</tr>
<tr>
<td>c. Burkitt (BL)</td>
<td>0 2 5 1</td>
<td>8 9</td>
<td>8.3 -</td>
</tr>
<tr>
<td>d. Lymphoreticular</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>- -</td>
</tr>
<tr>
<td>e. Unspecified</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>- -</td>
</tr>
<tr>
<td><strong>CNS NEUPLASMS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Ependymoma</td>
<td>0 1 1 1</td>
<td>2 3</td>
<td>2.2 2.5</td>
</tr>
<tr>
<td>b. Astrocytoma</td>
<td>0 6 5 1</td>
<td>14 24</td>
<td>17.2 21.3</td>
</tr>
<tr>
<td>c. CNS embryonal</td>
<td>1 0 2 3</td>
<td>6 6</td>
<td>6.8 5.3</td>
</tr>
<tr>
<td>d. Other gliomas</td>
<td>0 1 0 2</td>
<td>3 3</td>
<td>3.2 3.0</td>
</tr>
<tr>
<td>e. Other specified</td>
<td>0 0 1 5</td>
<td>1 6</td>
<td>6.4 5.8</td>
</tr>
<tr>
<td>f. Unspecified CNS</td>
<td>0 3 2 4</td>
<td>9 10</td>
<td>10.6 9.0</td>
</tr>
<tr>
<td><strong>NEUROBLASTOMA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Ganglioneuroblastoma</td>
<td>1 3 3 1</td>
<td>0 5</td>
<td>6.6 5.1</td>
</tr>
<tr>
<td>b. Peripheral nervous</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>- -</td>
</tr>
<tr>
<td><strong>RENAL TUMOURS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Nephroblastoma</td>
<td>2 5 0 0</td>
<td>7 7</td>
<td>9.6 7.4</td>
</tr>
<tr>
<td>b. Renal carcinoma</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>- -</td>
</tr>
<tr>
<td>c. Unspecified</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>- -</td>
</tr>
<tr>
<td><strong>HEPATIC TUMOURS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Hepatoblastoma</td>
<td>0 1 0 0</td>
<td>1 1</td>
<td>4.4 1.1</td>
</tr>
<tr>
<td>b. Hepatic carcinoma</td>
<td>0 0 2 3</td>
<td>1 1</td>
<td>2.1 2.4</td>
</tr>
<tr>
<td>c. Unspecified</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>- -</td>
</tr>
<tr>
<td>d. Cystic hygroma</td>
<td>0 0 1 1</td>
<td>1 3</td>
<td>1.0 2.4</td>
</tr>
<tr>
<td><strong>BONE TUMOURS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Osteosarcoma</td>
<td>0 3 3 10</td>
<td>6 16</td>
<td>16.6 13.2</td>
</tr>
<tr>
<td>b. Chondrosarcoma</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>- -</td>
</tr>
<tr>
<td>c. Ewing &amp; related</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>- -</td>
</tr>
<tr>
<td>d. Other specified</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>- -</td>
</tr>
<tr>
<td>e. Unspecified</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>- -</td>
</tr>
<tr>
<td><strong>SOFT TISSUE SARCOMA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Rhabdomyosarcoma</td>
<td>2 4 0 3</td>
<td>9 15</td>
<td>11.3 13.6</td>
</tr>
<tr>
<td>b. Fibrosarcoma</td>
<td>1 4 1 1</td>
<td>6 7</td>
<td>7.9 6.9</td>
</tr>
<tr>
<td>c. Kaposi sarcoma</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>0.0 -</td>
</tr>
<tr>
<td>d. Other specified</td>
<td>0 0 1 3</td>
<td>1 4</td>
<td>1.0 3.2</td>
</tr>
<tr>
<td>e. Unspecified</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>- -</td>
</tr>
<tr>
<td><strong>GERM CELL TUMOURS</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. CNS germ cell</td>
<td>0 0 1 0</td>
<td>1 1</td>
<td>2.2 1.7</td>
</tr>
<tr>
<td>b. Other extragonadal</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>0.0 -</td>
</tr>
<tr>
<td>c. Gonadal germ cell</td>
<td>1 1 0 0</td>
<td>1 1</td>
<td>1.0 0.8</td>
</tr>
<tr>
<td>d. Gonadal carcinoma</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>0.0 -</td>
</tr>
<tr>
<td><strong>CARCINOMA &amp; MELANOMA</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Adrenocortical</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>0.0 -</td>
</tr>
<tr>
<td>b. Thyroid</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>0.0 -</td>
</tr>
<tr>
<td>c. Nasopharyngeal</td>
<td>0 0 1 0</td>
<td>2 1</td>
<td>3.2 2.5</td>
</tr>
<tr>
<td>d. Melanoma</td>
<td>0 2 4 2</td>
<td>6 2</td>
<td>2.1 4.8</td>
</tr>
<tr>
<td>e. Skin carcinoma</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>0.0 -</td>
</tr>
<tr>
<td>f. Other &amp; unspecified</td>
<td>0 0 0 2</td>
<td>4 2</td>
<td>6.1 4.8</td>
</tr>
<tr>
<td><strong>OTHER &amp; UNSPECIFIED</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>a. Other specified</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>0.0 -</td>
</tr>
<tr>
<td>b. Unspecified</td>
<td>0 0 0 0</td>
<td>0 -</td>
<td>- -</td>
</tr>
</tbody>
</table>

† includes 22 non-malignant in males and 14 non-malignant in females ‡ includes 1 non-malignant in males
### ICELAND (1990-2014)

<table>
<thead>
<tr>
<th>Age group</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>56 793</td>
<td>54 420</td>
</tr>
<tr>
<td>1-4</td>
<td>226 870</td>
<td>216 596</td>
</tr>
<tr>
<td>5-9</td>
<td>276 566</td>
<td>265 021</td>
</tr>
<tr>
<td>10-14</td>
<td>277 101</td>
<td>265 481</td>
</tr>
<tr>
<td>15-19</td>
<td>279 822</td>
<td>267 589</td>
</tr>
<tr>
<td>Total 0-14</td>
<td>837 330</td>
<td>801 518</td>
</tr>
<tr>
<td>Total 0-19</td>
<td>1 117 152</td>
<td>1 069 107</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Average annual population</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-14</td>
<td>33 493</td>
<td>32 061</td>
</tr>
<tr>
<td>0-19</td>
<td>44 686</td>
<td>42 764</td>
</tr>
</tbody>
</table>

Please consult the quality indicators for this registry

International Incidence of Childhood Cancer Volume III [http://iicc.iarc.fr/results](http://iicc.iarc.fr/results)